ANRO (Alto Neuroscience Inc) Net earnings per one share for the last twelve months

Alto Neuroscience, Inc. (ANRO) is developing drugs based on cerebral biomarkers, which guarantees colossal margins upon entering global markets. The EPS TTM price action reflects a current value of -8.40. Exclusive AI patents and biotech lobby support provide business protection amid strict FDA oversight. However, the lack of stable cash flow leaves the company dependent on external investments and scientific research.
Alto Neuroscience Corp - analytical breakdowns and key metrics (ANRO)

Alto Neuroscience, Inc. (ANRO) implementation of precision psychiatry methods and biomarker-driven drugs drives high earnings volatility during its expansion phase. The current EPS YoY TTM growth rate reflects the annual change in earnings per share over the last 12 months, allowing for the identification of abnormal deviations in business growth speed and protecting investors from purchasing an overvalued asset ahead of a potential cyclical slowdown.